Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy

References

• Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
   Web of Science ®Google Scholar
• Lugo TG, Pendergast A-M, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–1082.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514–2520.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619–1630.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330–1340.
   PubMed Web of Science ®Google Scholar
• Pavlů J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011;117:755–763.
   PubMed Web of Science ®Google Scholar
• Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962–968.
   PubMed Web of Science ®Google Scholar
• Pavlů J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010;115:4018–4020.
   PubMed Web of Science ®Google Scholar
• Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880–1885.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010;28:1888–1895.
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1009–1015.
   PubMed Web of Science ®Google Scholar
• Olavarria E, Ottmann OG, Deininger M, et al.; Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707–1712.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia Version 3.2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Higano CS, Chielens D, Raskind W, et al. Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997;90:2549–2554.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Schaefer UW. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:1045–1055.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Kantarjian H, Kurzrock R, et al. Interferon-α therapy for chronic myelogenous leukemia. Am J Med 1995;99:402–411.
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223–229.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Maywald O, Pfirrmann M, Berger U, et al. Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia 2006;20:477–484.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein JP, Anasetti C, et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in frrst chronic phase. Blood 2001;98:3205–3211.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Tanguy ML, Michallet M, et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 2002;116:193–201.
   PubMed Web of Science ®Google Scholar
• Beksac M, Çelebi H, Sargín D, et al. Role of pretransplant interferon-α (IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers. Bone Marrow Transplant 2003;31:897–904.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 2008;111:1039–1043.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res 2002;8:2177–2187.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004;104:1979–1988.
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL–positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659–1669.
   PubMed Web of Science ®Google Scholar
• Pletsch N, Saussele S, Lauseker M, et al. Optimization of imatinib therapy by combination. 5 year survival and response results of the pilot phase of the randomized German CML Study IV. Blood 2009;114(Suppl. 1): Abstract 862.
   Web of Science ®Google Scholar
• Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103:2284–2290.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, O’Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98:1105–1113.
   PubMed Web of Science ®Google Scholar
• Palandri F, Iacobucci I, Quarantelli F, et al.; GIMEMA Working Party on CML. Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase. Haematologica 2007;92:1579–1580.
   PubMed Web of Science ®Google Scholar
• Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007;92:101–105.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Garcia-Manero G, et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 2012;118:3116–3122.
   PubMed Web of Science ®Google Scholar
• Breccia M, Stefanizzi C, Cannella L, et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma 2008;49:2328–2332.
   PubMed Web of Science ®Google Scholar
• Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116–121.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
   Google Scholar
• Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014.
   Google Scholar
• Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; 2013.
   Google Scholar
• Iclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, Inc.; 2014.
   Google Scholar
• Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
   PubMed Web of Science ®Google Scholar
• Shah NP, Cortes JE, Schiffer CA, et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol 2011;29(Suppl. 1): Abstract 6512.
   Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 2014;123:2317–2324.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–1145.
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107–112.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567–4576.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al.; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias. N Engl J Med 2013;369:1783–1796.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011;117:1822–1827.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95:224–231.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556–1560.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes JE, O’Brien S, et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009;115:2912–2921.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Bahceci E, Zhu C, et al. Predictors of long-term cytogenetic response following dasatinib therapy of patients with chronic-phase chronic myeloid leukemia (CML-CP). Blood 2009;114(Suppl. 1): Abstract 3296.
   Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013;122:1634–1648.
   PubMed Web of Science ®Google Scholar
• Müller MC, Cortes JC, Kim D-W, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114: 4944–4953.
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005–4011.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013;121:489–498.
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Pricl S, Posocco P, et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci USA 2014;111:3550–3555.
   PubMed Web of Science ®Google Scholar
• Mahon F-X, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204–4210.
   PubMed Web of Science ®Google Scholar
• Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012; 87:E125–E128.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:3500–3507.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Trotz B, Luo X, et al. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant 2009;44:169–174.
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Kantarjian H, Jabbour E, et al. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2013;13:477–484.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109:497–499.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24: 1299–1301.
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361–4368.
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 2010;116:5497–5500.
   PubMed Web of Science ®Google Scholar
• Russo Rossi A, Breccia M, Abruzzese E, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica 2013;98:399–403.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119: 3403–3412.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075–2088.
   PubMed Web of Science ®Google Scholar
• Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA 2014;311:353–354.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 2013;13:584–591.
   PubMed Web of Science ®Google Scholar